Back to all Current clinical trials
Back to all Current clinical trials
frontMIND - A new treatment for newly diagnosed lymphoma
Lymphoma
The frontMIND trial is testing a new treatment for patients who have been recently diagnosed with a type of blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL). The study investigates the safety and effectiveness of investigational drug tafasitamab plus lenalidamide. The study aims to determine if addition of the investigational drug to standard therapy for DLBCL improves treatment outcomes for patients compared to standard therapy on its own.
- Category
-
Trial status
Active, not recruiting
-
Trial phase
Phase 3 Drug TrialLate stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
- Registry listing
Trial contact details
-
Contact person
Kim Green - Clinical Research Coordinator
What you need to know
Who can take part?
- People who have been recently diagnosed and not begun treatment for DLBCL, grade 3b Follicular Lymphoma and certain rare forms of B-cell lymphoma
- People with no prior history of blood cancers or other cancers, aside from some skin cancers
- People of reproductive potential must avoid pregnancy during the study
What is involved for you?
Participants will be randomly assigned to receive investigational drug plus standard chemotherapy, by intravenous infusion, or standard chemotherapy alone. They also undergo the following tests:
- Physical exams
- Heart rate & blood pressure
- Electrocardiogram
- Blood tests
- Urine tests
- Imaging scans: PET/CT
- CT or MRI scan
- Echocardiogram
- Bone marrow biopsy
- A tumour biopsy may be required, if samples from a diagnostic biopsy are not available
- Questionnaires
